{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:56:20Z","timestamp":1791082580623,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG070873-01A1"],"award-info":[{"award-number":["R01 AG070873-01A1"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["2021-2026"],"award-info":[{"award-number":["2021-2026"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006370","name":"Small Business Innovation Research","doi-asserted-by":"publisher","award":["R43 AG071045-01A1"],"award-info":[{"award-number":["R43 AG071045-01A1"]}],"id":[{"id":"10.13039\/100006370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006370","name":"Small Business Innovation Research","doi-asserted-by":"publisher","award":["2021-2023"],"award-info":[{"award-number":["2021-2023"]}],"id":[{"id":"10.13039\/100006370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Phosphodiesterase 2A (PDE2A) represents a novel target for new therapies addressing psychiatric disorders. To date, the development of PDE2A inhibitors suitable for human clinical evaluation has been hampered by the poor brain accessibility and metabolic stability of the available compounds.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Corticosterone (CORT)-induced neuronal cell lesion and restraint stress mouse model were used to measure the neuroprotective effect in cells and antidepressant-like behavior in mice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The cell-based assay showed that both Hcyb1 and PF were potent in protecting cells against stress hormone CORT insults by stimulating cAMP and cGMP signaling in hippocampal cells (HT-22). Administration of both compounds before treatment of CORT to cells increased cAMP\/cGMP, VASP phosphorylation at Ser239 and Ser157, cAMP response element binding protein phosphorylation at Ser133, and brain derived neurotrophic factor BDNF expression. Further in vivo study showed that both Hcyb1 and PF displayed \u00adantidepressant- and anxiolytic-like effects against restraint stress as indicated by reduced immobility time in the forced swimming and tail suspension tasks as well as increased open arm entries and time spent in open arms and holes visit in elevated plus maze and hole-board tests, respectively. The biochemical study confirmed that these antidepressant- and anxiolytic-like effects of Hcyb1 and PF were related to cAMP and cGMP signaling in the hippocampus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The results extend the previous studies and validate that PDE2A is a tractable target for drug development in the treatment of emotional disorders such as depression and anxiety.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijnp\/pyad020","type":"journal-article","created":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T02:17:08Z","timestamp":1684549028000},"page":"415-425","source":"Crossref","is-referenced-by-count":7,"title":["Characterization of 2 Novel Phosphodiesterase 2 Inhibitors Hcyb1 and PF-05180999 on Depression- and Anxiety-Like Behavior"],"prefix":"10.1093","volume":"26","author":[{"given":"Yuqing","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Rutgers, the State University of New Jersey , Newark, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Rutgers, the State University of New Jersey , Newark, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Rutgers, the State University of New Jersey , Newark, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav P","family":"Acharya","sequence":"additional","affiliation":[{"name":"Chemical Engineering School for the Engineering of Matter, Transport, and Energy, Arizona State University , Tempe, Arizona , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Arizona Center for Drug Discovery, College of Pharmacy, University of Arizona , Tucson, Arizona , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4128-7269","authenticated-orcid":false,"given":"Chang-Guo","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky , Lexington, Kentucky , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghong","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Rutgers, the State University of New Jersey , Newark, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu","family":"Du","sequence":"additional","affiliation":[{"name":"FD NeuroTechnologies Consulting and Services , Inc., Columbia, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongwei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Case Western Reserve University , Cleveland, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Rutgers, the State University of New Jersey , Newark, New Jersey , USA"},{"name":"Department of Pathology, Case Western Reserve University , Cleveland, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"2023122706055303200_CIT0001","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/PPA.S29716","article-title":"Treatment-resistant depression: therapeutic trends, challenges, and future directions","volume":"6","author":"Al-Harbi","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"2023122706055303200_CIT0002","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1021\/ml500262u","article-title":"Structure-based design of a potent, selective, and brain penetrating PDE2 inhibitor with demonstrated target engagement","volume":"5","author":"Buijnsters","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"2023122706055303200_CIT0003","doi-asserted-by":"crossref","first-page":"14509","DOI":"10.1016\/S0021-9258(17)36652-8","article-title":"cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets","volume":"269","author":"Butt","year":"1994","journal-title":"J Biol Chem"},{"key":"2023122706055303200_CIT0004","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1038\/s41380-020-00997-9","article-title":"Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders","volume":"26","author":"Delhaye","year":"2021","journal-title":"Mol Psychiatry"},{"key":"2023122706055303200_CIT0005","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbr.2014.03.042","article-title":"Protective effects of phosphodiesterase 2 inhibitor on depression- and anxiety-like behaviors: Involvement of antioxidant and anti-apoptotic mechanisms","volume":"268","author":"Ding","year":"2014","journal-title":"Behav Brain Res"},{"key":"2023122706055303200_CIT0006","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.neuron.2014.01.027","article-title":"The genetics of major depression","volume":"81","author":"Flint","year":"2014","journal-title":"Neuron"},{"key":"2023122706055303200_CIT0007","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40273-021-01019-4","article-title":"The economic burden of adults with major depressive disorder in the United States (2010 and 2018)","volume":"39","author":"Greenberg","year":"2021","journal-title":"PharmacoEcon"},{"key":"2023122706055303200_CIT0008","first-page":"Cd004851","article-title":"Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents","volume":"3","author":"Hetrick","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2023122706055303200_CIT0009","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/cns.12864","article-title":"A novel PDE9 inhibitor WYQ-C36D ameliorates corticosterone-induced neurotoxicity and depression-like behaviors by cGMP-CREB-related signaling","volume":"24","author":"Huang","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"2023122706055303200_CIT0010","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.neuropharm.2018.09.039","article-title":"Inhibition of phosphodiesterase 2 reverses gp91phox oxidase-mediated depression- and anxiety-like behavior","volume":"143","author":"Huang","year":"2018","journal-title":"Neuropharmacology"},{"key":"2023122706055303200_CIT0011","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.bmcl.2018.12.018","article-title":"Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: The neuroprotective and anxiolytic-like effects","volume":"29","author":"Huang","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"2023122706055303200_CIT0012","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BFb0033670","article-title":"Cyclic GMP as substrate and regulator of cyclic nucleotide phosphodiesterases (PDEs)","volume":"135","author":"Juilfs","year":"1999","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"2023122706055303200_CIT0013","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.brainres.2005.01.015","article-title":"Involvement of cyclic GMP-dependent protein kinase in nitrous oxide-induced anxiolytic-like behavior in the mouse light\/dark exploration test","volume":"1038","author":"Li","year":"2005","journal-title":"Brain Res"},{"key":"2023122706055303200_CIT0014","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/cns.12863","article-title":"The neuroprotective and antidepressant-like effects of Hcyb1, a novel selective PDE2 inhibitor","volume":"24","author":"Liu","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"2023122706055303200_CIT0015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1124\/jpet.108.137208","article-title":"Reversal of oxidative stress-induced anxiety by inhibition of phosphodiesterase-2 in mice","volume":"326","author":"Masood","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"2023122706055303200_CIT0016","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1124\/jpet.109.156729","article-title":"Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling","volume":"331","author":"Masood","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"2023122706055303200_CIT0017","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0091-3057(93)90310-P","article-title":"MK-801 and enantiomers: potential antidepressants or false positives in classical screening models?","volume":"46","author":"Panconi","year":"1993","journal-title":"Pharmacol Biochem Behav"},{"key":"2023122706055303200_CIT0018","doi-asserted-by":"crossref","first-page":"e24331","DOI":"10.2196\/24331","article-title":"Virtual reality behavioral activation as an intervention for major depressive disorder: case report","volume":"7","author":"Paul","year":"2020","journal-title":"JMIR Ment Health"},{"key":"2023122706055303200_CIT0019","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2174\/157015911798376271","article-title":"cGMP signaling, phosphodiesterases and major depressive disorder","volume":"9","author":"Reierson","year":"2011","journal-title":"Curr Neuropharmacol"},{"key":"2023122706055303200_CIT0020","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fncel.2019.00432","article-title":"Phosphodiesterase-2 inhibitor bay 60-7550 ameliorates A\u03b2-induced cognitive and memory impairment via regulation of the HPA Axis","volume":"13","author":"Ruan","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"2023122706055303200_CIT0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1471-4159.2010.07080.x","article-title":"CREB: a multifaceted regulator of neuronal plasticity and protection","volume":"116","author":"Sakamoto","year":"2011","journal-title":"J Neurochem"},{"key":"2023122706055303200_CIT0022","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/PL00005234","article-title":"Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO\/cGMP effects","volume":"358","author":"Smolenski","year":"1998","journal-title":"Naunyn-Schmiedeb Arch. Pharmacol"},{"key":"2023122706055303200_CIT0023","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuroscience.2012.09.011","article-title":"The distribution of phosphodiesterase 2A in the rat brain","volume":"226","author":"Stephenson","year":"2012","journal-title":"Neuroscience"},{"key":"2023122706055303200_CIT0024","first-page":"823","article-title":"Economic burden of treatment-resistant depression on the U.S. health care system","volume":"25","author":"Sussman","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"2023122706055303200_CIT0025","doi-asserted-by":"crossref","first-page":"12887","DOI":"10.1021\/acs.jmedchem.0c01272","article-title":"[1,2,4]Triazolo[1,5-a]pyrimidine phosphodiesterase 2A inhibitors: structure and free-energy perturbation-guided exploration","volume":"63","author":"Tresadern","year":"2020","journal-title":"J Med Chem"},{"key":"2023122706055303200_CIT0026","doi-asserted-by":"crossref","DOI":"10.23970\/AHRQEPCCER224","volume-title":"AHRQ comparative effectiveness reviews treatment of depression in children and adolescents: a systematic review","author":"Viswanathan","year":"2020"},{"key":"2023122706055303200_CIT0027","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.brainres.2008.01.104","article-title":"Curcumin protects against glutamate excitotoxicity in rat cerebral cortical neurons by increasing brain-derived neurotrophic factor level and activating TrkB","volume":"1210","author":"Wang","year":"2008","journal-title":"Brain Res"},{"key":"2023122706055303200_CIT0028","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/978-3-642-17969-3_19","article-title":"Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders","volume":"204","author":"Xu","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"2023122706055303200_CIT0029","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1017\/S146114571200065X","article-title":"Phosphodiesterase-2 inhibitor reverses corticosterone-induced neurotoxicity and related behavioural changes via cGMP\/PKG dependent pathway","volume":"16","author":"Xu","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"2023122706055303200_CIT0030","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.neurobiolaging.2014.08.028","article-title":"Inhibition of phosphodiesterase 2 reverses impaired cognition and neuronal remodeling caused by chronic stress","volume":"36","author":"Xu","year":"2015","journal-title":"Neurobiol Aging"},{"key":"2023122706055303200_CIT0031","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2174\/1381612820666140826115245","article-title":"The roles of phosphodiesterase 2 in the central nervous and peripheral systems","volume":"21","author":"Zhang","year":"2015","journal-title":"Curr Pharm Des"},{"key":"2023122706055303200_CIT0032","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/978-3-319-58811-7_12","article-title":"The role of phosphodiesterase-2 in psychiatric and neurodegenerative disorders","volume":"17","author":"Zhang","year":"2017","journal-title":"Adv Neurobiol"},{"key":"2023122706055303200_CIT0033","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1007\/s00213-019-05401-1","article-title":"Phosphodiesterase 2 inhibitor Hcyb1 reverses corticosterone-induced neurotoxicity and depression-like behavior","volume":"237","author":"Zhu","year":"2020","journal-title":"Psychopharmacology (Berl)"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyad020\/50528585\/pyad020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/26\/6\/415\/54893842\/pyad020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/26\/6\/415\/54893842\/pyad020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T06:06:23Z","timestamp":1703657183000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/26\/6\/415\/7174198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,5,19]]},"published-print":{"date-parts":[[2023,6,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyad020","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,5,19]]}}}